These findings suggest that “TNF inhibition is not effective in ameliorating symptoms of OA of the knee in patients with clinical features of inflammation in a timeframe of 16 weeks,” said the presenter.

Guselkumab improves axial symptoms relative to placebo in people with axial psoriatic arthritis and radiographic evidence of sacroiliitis, shows a post-hoc analysis of the DISCOVER-1 and DISCOVER-2 studies.

People with KOA frequently report that their clinical symptoms were sensitive to weather.

Findings from a randomized trial show that the STEP-KOA exercise program, with intensification of the intervention for participants not meeting response criteria, may improve the symptoms of knee osteoarthritis.

Some patients with rheumatoid arthritis continue to experience residual symptoms despite achieving treat-to-target goals, but there is a paucity of evidence on the exact prevalence of these symptoms and their impact, report the authors of a systematic review.

Anxiety and depressive symptoms are associated with pain and disability but not active joint count or biomarkers of inflammation in adolescents with juvenile idiopathic arthritis, researchers report.

Researchers have identified discrepancies between patient and physician perspectives of bother associated with the different symptoms of psoriatic disease.

Depressive symptoms are common in adolescents with juvenile idiopathic arthritis and could predict future pain and disability, suggests an analysis of the Childhood Arthritis Prospective Study.

Results of a post-hoc analysis suggest that symptoms of depression are associated with increased flare risk after tapering tumor necrosis factor inhibitors among patients with rheumatoid arthritis.

In favor of treating people with subclinical RA, speaking together with V Michael Holers (University of Colorado, Boulder, Denver, USA), Kevin Deane (University of Colorado) believes “we should try and prevent or ameliorate clinical RA by treating in a stage-specific manner pre-RA autoimmune processes that may have their own symptoms and tissue injury,” adding that treating at a stage even when inflammatory arthritis is not present could still provide benefits such as reduced pain or fatigue.

Risankizumab was also associated with significantly greater improvements in skin symptoms – as measured by the proportion of patients achieving a 75%, 90%, or 100% reduction in the Psoriasis Area and Severity Index (PASI) score – compared with placebo.

Overall, the JUVE-BASIS results “support baricitinib as a treatment for signs and symptoms of JIA,” said Ramanan, noting that its oral route of administration is “more palatable to the children and families of children with juvenile arthritis” than other treatment options. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group ACR Convergence 2022; Philadelphia, Pennsylvania, USA: November 10–14

Hanns L et al. Rheumatology (Oxford) 2018; Advance online publication. doi: 10.1093/rheumatology/key088

The most commonly occurring AEs were myalgia (n=3), flu-like symptoms (n=2), and fever (n=2).

Nevertheless, there was greater improvement in knee OA overall and more satisfaction with symptoms and treatment in the PARTNER group than with usual care, the investigators say.

Mease P et al. Ann Rheum Dis 2018; Advance online publication. doi: 10.1136/annrheumdis-2017-212687

McAlindon TE et al. Osteoarthritis Cartilage 2018. doi: 10.1016/j.joca.2018.05.001

AS starts gradually, and its early symptoms are mild.

Nevertheless, “[c]onsidering the high mortality risk following HF hospitalization, our novel findings suggest that clinicians involved in the care of SSc patients should pay attention to associated symptoms and signs of HF,” concludes the team. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group Arthritis Care Res 2022; doi:10.1002/acr.25016